KATHLEEN RAIS: Open Payments
NPI 1366601437 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$8,089 in 384 payments from 26 companies in 2025. Trend: 2023 $4,918 · 2024 $5,977 · 2025 $8,089
Food & beverage: $6,335Consulting: $1,370Education: $385
| Company | Payments | Amount |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 4 | $1,391 |
| ABBVIE INC. | 56 | $835 |
| UCB, Inc. | 25 | $704 |
| Janssen Biotech, Inc. | 30 | $672 |
| PFIZER INC. | 26 | $533 |
| Regeneron Healthcare Solutions, Inc. | 26 | $514 |
| Galderma Laboratories, L.P. | 24 | $359 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 20 | $341 |
| Arcutis Biotherapeutics, Inc. | 20 | $333 |
| Incyte Corporation | 23 | $325 |
Products named: DUPIXENT, Bimzelx, TREMFYA, CIBINQO, RINVOQ, SKYRIZI, Zoryve, OPZELURA.
Industry payments across TX — which companies pay providers there.
